The early-stage startup offers advanced microbiome and precision medicine R&D services to improve clinical outcomes for a range of therapeutics. Nexilico's computational technologies predict interactions between the gut microbiome and therapeutics, which helps understand gut microbiome-mediated drug metabolism for diagnostics and treatment purposes. The company has received multiple SBIR/STTR grants from NIH and NSF for its innovative technologies.